The latest price target for Enveric Biosciences (NASDAQ:ENVB) was reported by HC Wainwright & Co. on January 30, 2024. The analyst firm set a price target for $10.00 expecting ENVB to rise to within 12 months (a possible 2935.82% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Enveric Biosciences (NASDAQ:ENVB) was provided by HC Wainwright & Co., and Enveric Biosciences initiated their buy rating.

There is no last upgrade for Enveric Biosciences

The last downgrade for Enveric Biosciences Inc happened on March 8, 2022 when Aegis Capital changed their price target from $7 to $0.2 for Enveric Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enveric Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enveric Biosciences was filed on January 30, 2024 so you should expect the next rating to be made available sometime around January 30, 2025.

While ratings are subjective and will change, the latest Enveric Biosciences (ENVB) rating was a initiated with a price target of $0.00 to $10.00. The current price Enveric Biosciences (ENVB) is trading at is $0.33, which is within the analyst’s predicted range.